Literature DB >> 16834828

Disease control in asthmatic children seen in private practice in Switzerland.

Alexander Moeller1, Claudia Steurer-Stey, Herbert Suter, Michael Hofer, Manuela Peter, Joanne Brooks-Wildhaber, Jürg Hammer, Johannes H Wildhaber.   

Abstract

BACKGROUND: Asthma is the most common chronic childhood disease in Switzerland with a prevalence of 10%. Asthma has a high economic burden accounting for high medical costs. Assessment of disease control is likely to be of help in the implementation of strategies to improve asthma. Therefore, we aimed to evaluate asthma control and therapy regimens among children in private practice.
METHODS: We assessed asthma control as well as therapy regimens in 575 asthmatic children in an experience programme in Switzerland by using an abbreviated questionnaire based on the asthma control questionnaire and the child health questionnaire on Visit 1 and Visit 2.
RESULTS: Good asthma control at Visit 1 was only present in 25.7% of asthmatic children. Occasional asthma symptoms, limitation of physical activity, nocturnal awakening and anxiety of the parent was present in 80.5%, 41.2%, 46.8% and 57% of the children, respectively. After adjustment of therapy regimens at Visit 1, mainly by adding a leukotriene receptor antagonist, asthma control was reported to be much better in 53.4% of the children at Visit 2.
CONCLUSIONS: As asthma control is inadequately achieved within a major portion of asthmatic children, it is imperative to find measures to improve asthma control and hence, to reduce the burden of disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16834828     DOI: 10.1185/030079906X112633

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  1 in total

1.  Reported Exercise-Related Respiratory Symptoms and Exercise-Induced Bronchoconstriction in Asthmatic Children.

Authors:  Demet Inci; Refoel Guggenheim; Derya Ufuk Altintas; Johannes H Wildhaber; Alexander Moeller
Journal:  J Clin Med Res       Date:  2017-04-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.